References
- Al-Abri S, Meier KH, Colby JM, et al. Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels. Clin Toxicol. 2014;52(10):1292–1295.
- Hondebrink L, Nugteren-van Lonkhuyzen JJ, Rietjens SJ, et al. Fatalities, cerebral hemorrhage, and severe cardiovascular toxicity after exposure to the new psychoactive substance 4-fluoroamphetamine: a prospective cohort study. Ann Emerg Med. 2018;71(3):294–305.
- Madias JE. Takotsubo syndrome due to 4-fluoroamphetamine. Clin Toxicol. 2015;53(2):136–136.
- Lelievre B, Richeval C, Coulon A, et al. Case report on two-cathinones abuse: MPHP and N‑ethyl‑4′methylnorpentedrone, with a fatal outcome. Forensic Toxicol. 2020;38:243–254.
- Begeman A, Franssen E. Lack of detection of new amphetamine-like drugs using conventional urinary immunoassays. Ther Drug Monit. 2018;40(1):135–139.